Collegium Pharmaceutical (COLL) PT Lowered to $48 at Barclays
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Crude Inventory Fell 3.06 Million Barrels Last Week - EIA
- US orders diplomats to depart Saudi Arabia amid Houthi strikes
Barclays flags an "attractive entry point" in this pharma stock
August 20, 2026 3:00 PM EDTBarclays reiterated an Overweight rating on a pharmaceutical name in a note this week, arguing the roughly 20% share decline since second-quarter results has gone too far.
Collegium Pharma (NASDAQ: COLL) (NASDAQ: COLL) is the stock in question.
"Pain-fueled volatility overdone:... More



